<DOC>
	<DOCNO>NCT01554124</DOCNO>
	<brief_summary>This phase I-II multicenter international trial design study pharmacokinetics meropenem characterize safety profile meropenem treatment infant ≤ 90 day postnatal age probable confirm bacterial meningitis .</brief_summary>
	<brief_title>Pharmacokinetics Safety Meropenem Infants Below 90 Days Age With Probable Confirmed Meningitis</brief_title>
	<detailed_description>The primary objective study pharmacokinetics ( plasma cerebrospinal fluid ) meropenem infant ≤ 90 day postnatal age probable confirm bacterial meningitis characterize safety profile meropenem treatment infant ≤ 90 day postnatal age probable confirm bacterial meningitis . The secondary objective : - To describe efficacy meropenem day 3 , end allocate treatment ( EOAT ) , test cure ( TOC ) follow ( FU ) . - To evaluate survival FU - To evaluate episode meningitis ( relapse new infection ) occur TOC FU visit - To define organisms cause neonatal meningitis - To describe antibacterial susceptibility meningitis-causing organism describe clinical microbiological response accord - To evaluate mucosal colonization resistant organisms treatment meropenem - To evaluate bacterial eradication - To evaluate functional genetic parameter may affect response therapy</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<criteria>Informed consent form sign parents/carers Chronological age 90 day inclusive The presence : clinical sign consistent BM ( hyperthermia hypothermia temperature instability PLUS 1 neurological finding among coma , seizure , neck stiffness , apnoea , bulge fontanelle ) , OR CSF pleocytosis ( ≥ 20 cells/mm3 ) OR positive Gram stain CSF . Presence CSF device Proven viral fungal meningitis Severe congenital malformation infant expect survive 3 month Other situation treat physician considers different empiric antibiotic regimen necessary Known intolerance contraindication study medication Participation clinical study investigational medicinal product Renal failure requirement haemofiltration peritoneal dialysis Meningitis organism know resistant meropenem</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>90 Days</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Neonates</keyword>
	<keyword>Meropenem</keyword>
</DOC>